Neurocrine Biosciences Inc vs IAC/Interactivecorp — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while IAC/Interactivecorp trades at $44.87 (market cap $3.32B). The key difference: Neurocrine Biosciences Inc is far larger — about 5.2× IAC/Interactivecorp's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, IAC/Interactivecorp nearer its low. Which is the better fit depends on your goals.
| NBIX | PPLI | |
|---|---|---|
Market Cap | $17.40B | $3.32B |
Sector | Health | Media |
52-Week High | $180.55 | $47.62 |
52-Week Low | $123.10 | $31.52 |
Enterprise Value | $16.49B | $3.63B |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →